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Abstract: Symptomatic venous thromboembolism (VTE) occurs in five percent of children treated
for acute lymphoblastic leukemia (ALL), but whether a genetic predisposition exists across different
ALL treatment regimens has not been well studied. Methods: We undertook a genome-wide
association study (GWAS) meta-analysis for VTE in consecutively treated children in the Nordic/Baltic
acute lymphoblastic leukemia 2008 (ALL2008) cohort and the Australian Evaluation of Risk of ALL
Treatment-Related Side-Effects (ERASE) cohort. A total of 92 cases and 1481 controls of European
ancestry were included. Results: No SNPs reached genome-wide significance (p < 5 × 10−8) in
either cohort. Among the top 34 single-nucleotide polymorphisms (SNPs) (p < 1 × 10−6), two loci
had concordant effects in both cohorts: ALOX15B (rs1804772) (MAF: 1%; p = 3.95 × 10−7) that
influences arachidonic acid metabolism and thus platelet aggregation, and KALRN (rs570684) (MAF:
1%; p = 4.34 × 10−7) that has been previously associated with risk of ischemic stroke, atherosclerosis,
and early-onset coronary artery disease. Conclusion: This represents the largest GWAS meta-analysis
conducted to date associating SNPs to VTE in children and adolescents treated on childhood ALL
protocols. Validation of these findings is needed and may then lead to patient stratification for VTE
preventive interventions. As VTE hemostasis involves multiple pathways, a more powerful GWAS is
needed to detect combination of variants associated with VTE.
Keywords: acute lymphoblastic leukemia; child; genome-wide association study; single-nucleotide
polymorphism; venous thromboembolism
1. Introduction
Symptomatic venous thromboembolism (VTE) is a well-recognised complication that can lead
to substantial morbidity and potential mortality during therapy for childhood acute lymphoblastic
leukemia (ALL) [1–4]. Children and adolescents who experience VTE during ALL treatment are at
risk of interruption or discontinuation of chemotherapy, which can lead to decreased survival [5].
Malignancy itself along with treatment-related factors such as steroids, asparaginase, immobilization,
and use of central venous lines (CVLs) increase the risk of VTE [6,7]. In addition, older age is
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a significant risk factor for VTE [2–4]. However, it is unknown whether common germline DNA
variants play a significant role in development of thrombosis during treatment for ALL [4,8]. There is a
paucity of genetic studies, especially a lack of studies based on genome-wide approaches in children
with VTE, and particularly in children who share a similar phenotype [4,8,9].
Accordingly, we conducted a genome-wide association study (GWAS) meta-analysis to identify
single-nucleotide polymorphisms that were associated with risk of VTE for children and adolescents
treated on childhood ALL protocols in two international cohorts.
2. Results
2.1. Patient Characteristics of Nordic Society of Pediatric Hematology and Oncology (NOPHO) and Australian
VTE in ALL Cohorts
To study the genetic determinants of symptomatic VTE in acute lymphoblastic leukemia,
we analysed data from two published ALL VTE cohorts [2–4]. Consort diagrams for patient selection in
the GWAS are outlined in Figures 1 and 2 and the baseline demographics of the two cohorts are detailed
in Table 1. The cohort consisted of 1573 children and adolescents, aged between 1 and 18 years—92 of
whom had experienced VTE at a median time of 80 days from diagnosis of ALL/LBL to occurrence of
VTE, while 1481 children did not experience VTE during first-line ALL/LBL treatment. The clinical
practice for both cohorts was to site central lines early in treatment. Therefore, this study is not able
to study the impact of central line insertion on the incidence of VTE in ALL. There was no routine
thromboprophylaxis for patients in either cohort nor replacement of antithrombin III for patients in
either cohort.
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Figure 1. Consort diagram of 866 individuals in the Nordic Society of Pediatric Hematology and 
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Figure 1. Consort diagram of 866 individuals in the Nordic Society of Pediatric Hematology and
Oncology (NOPHO) genome-wide association study (GWAS) discovery cohort for symptomatic
venous thromboembolism (VTE). a NOPHO clinical cohort as described in Rank, et al., 2018 and
Tuckuviene, et al., 2016. In addition, there were three individuals who experienced VTE but who
did not fulfil all inclusion criteria f r the protocol (two mixed-phenotype acute leukemia (MPAL),
one pre-treatment). b Caucasian ethnicity defined by CEU, (Utah esidents (CEPH) with Northern
and Western European A cestry) clustering in principal component analysis (see methods). The final
NOPHO GWAS cohort for symptomatic VTE comprised 61 cases (those who experienced symptomatic
VTE during first-line ALL treatment) and 805 controls (those who did not experience symptomatic VTE
during first-line ALL treatment).
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Table 1. Demographics of children and adolescents experiencing VTE * Age is rounded to closest year
in the ERASE cohort, as initial age values were in months. † Other = lineage not known, includes
mixed-phenotype acute leukemia (n = 7 in ERASE cohort, n = 2 in NOPHO cohort), ALL/LBL (lineage
not specified). For comparison of NOPHO and ERASE cohorts, two-sided p values < 0.05 were
considered significant; NC = p value was not calculated. Abbreviations: IQR, interquartile range;
ALL, acute lymphoblastic leukemia; LBL, lymphoblastic lymphoma; T21, Trisomy 21; Ph + ALL,
Philadelphia chromosome (t(9;22) positive ALL; CVST, cerebral venous sinus thrombosis; DVT, deep
venous thrombosis; PE, pulmonary embolus. ANZCCSG, Australian and New Zealand Children’s
Cancer Study Group; ANZCHOG, Australian and New Zealand Children’s Hematology and Oncology
Group; AIEOP, Associazone Italiana Ematologia Oncologia Pediatrica; BFM, Berlin-Frankfurt-Münster;
COG, Children’s Oncology Group; NOPHO, Nordic Society of Pediatric Hematology and Oncology.
Clinical Feature Category GWAS Cohort (Total n = 1573) p Value
ERASE NOPHO
VTE
Yes 31 61
0.033No 676 805
Age at diagnosis
(years *)
Median (range) 5 (1−18) 4 (1−17)
0.75IQR 3–9 2–8
Sex
Female 337 394
0.419Male 370 472
Diagnosis
B-ALL 620 752
NC
B-LBL 4 0
T-ALL 60 112
ALL/LBL other † 15 2
T-LBL 8 0
Cytogenetics
ETV6-RUNX1 fusion 76 194
NC
High hyperdiploidy 191 260
Hypodiploid 10 10
KMT2A (MLL) gene rearrangement 12 0
Normal 179 150
Ph + ALL 5 0
Cytogenetics—no result 68 69
Cytogenetics—other 150 183
Constitutional T21 16 0
VTE location
CVST 9 22
0.184DVT 21 31
PE 1 8
Study protocol
ANZCCSG study 7 193
NOPHO ALL2008
n = 866
NC
ANZCHOG study 8 427
BFM 95 59
COG A5971 2
AIEOP-BFM study 9 26
When analysing time to VTE within each cohort, the ERASE cohort had a median time of onset from
cancer diagnosis to VTE diagnosis of 35 days (interquartile range (IQR) 25−164 days, range 1−731 days)
while the NOPHO cohort had a median onset from ALL diagnosis to VTE diagnosis of 109 days (IQR
51−137 days, range 24−363 days) (p = 0.006).
Most VTE events were deep venous thromboses (n = 52, 56.5% of VTE cases), with 31 cases of
cerebral venous sinus thrombosis (CVST) (33.7%), and nine cases of pulmonary emboli (PE) (9.8%).
Central venous line (CVL)-associated VTE, defined as a VTE occurring in the vein in which a CVL was
placed, occurred in a similar proportion of patients in each cohort—46% in the NOPHO2008 compared
to 44% in the ERASE cohort [2,4]. All patients listed in Table 1 were included in the respective GWA
studies and subsequent meta-analysis (METAL analysis).
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Figure 2. Consort diagram of 707 individuals in the Evaluation of Risk of ALL Treatment-related
Side-Effects (ERASE) GWAS discovery cohort for symptomatic VTE. a ERASE clinical cohort described
in Mateos, et al., 2019. b Pi-hat threshold >0.2. c Non-Caucasian ancestry defined as per 1000 Genomes
data. After quality control and filtering for ethnicity, there were 707 individuals of Caucasian ancestry
in the ERASE GWAS analysis.
2.2. METAL Analysis of GWA Studies of NOPHO and Australian VTE Cohorts
The METAL analysis [10] of NOPHO and ERASE ALL cohorts yielded results for 10, 922,
653 single-nucleotide polymorphisms (SNPs), and were ranked according to descending METAL
p value. To reduce the risk of confounding due to population stratification, each individual cohort
analysis and the METAL analysis was performed after exclusion of individuals of non-Caucasian
ancestry. No SNPs reached genome-wide association significance (p < 5 × 10−8). In total, there were
34 SNPs with a p value < 10−6 (listed in Table 2 and Supplementary Table S1). These corresponded to two
loci, taking into account the linkage disequilibrium (LD) of associated SNPs (Table 2). Supplementary
Table S1 includes SNPs that had p values from the METAL analysis of p < 5 × 10−6.
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Table 2. Top single-nucleotide polymorphisms (SNPs) in VTE meta-analysis, p < 1 × 10−6. Top SNPs associated with risk of VTE in ALL/LBL (note only top
SNP per loci (lowest p value) included, significance level p < 1 × 10−6). “Chr”, chromosome; “Position”, genomic position; “SNP ID”, rs identification number
for single-nucleotide polymorphism; “Allele 1” and “Allele 2” refer to nomenclature from METAL meta-analysis software, where Allele 1 is the Reference allele;
“MAF”, minor allele frequency, as per Genomic Coordinates in SNPNexus database (http://www.snp-nexus.org) which is synchronised with the UCSC human
genome annotation database (http://genome.ucsc.edu); “StdError”, standard error; “Direction” refers to direction of effect of the SNP in each cohort, thus “++”
refers to concordant positively-associated effect with VTE risk. SNPs were excluded from this table if the SNP was only able to be analysed in one cohort within the
meta-analysis. “OR”, odds ratio; “Lower 95C”, lower 95% confidence interval of OR; “Upper 95%CI”, upper 95% confidence interval of OR; “Gene” and “location”
refer to consensus gene and location of the SNP in relation to introns/exons of the associated gene, determined through SNPnexus cross-referencing of UCSC, Refseq
and Ensembl databases. Where there was discordance, the information from dbSNP 151 was used. “Intronic”, located in the intron of a coding gene; “3utr”, located
within 3 prime untranslated region.
Chr Position SNP ID Gene Location
Allele
MAF Cohort Effect Std Err p value Direction OR Lower95%CI
Upper
95%CI1 2
chr17 8,048,687 rs1804772 ALOX15B 3utr a c 0.01
Combined 2.09 0.41 3.95 × 10−7 ++ 8.1 3.61 18.18
ERASE 2.8 0.64 9.38 × 10−5
NOPHO 2.1 0.55 1.38 × 10−4
chr3 124,403,999 rs570684 KALRN intronic t c 0.01
Combined −2.18 0.43 4.34 × 10−7 – 0.11 0.05 0.26
ERASE −17.85 18.46 8.93 × 10−2
NOPHO −2 0.46 1.17 × 10−5
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The most strongly associated SNP in the METAL analysis was rs1804772 (p = 3.95 × 10−7,
minor allele frequency (MAF) 1%, Figure 3) within the ALOX15B gene at chromosome 17p13.1.
ALOX15B codes for arachidonate 15-lipoxygenase type B. The top SNP rs1804772 is found in the 3′
untranslated region of ALOX15B and was associated with an increased risk of VTE (OR 8.1 (95%CI
4.6–18.2)).
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The MAF of these SNPs in comparison to reference populations is presented in Table 3.
Table 3. Minor allele frequencies for ALOX15B and KALRN SNPs in reference populations.
Study/Population
ALOX15B KALRN
rs1804772
(3′ Prime UTR
Variant) C > A
rs73972650
(Intron
Variant) A > G
rs7225107
(Coding) A >
G,T
rs140958758
(3′Downstream)
A > C
rs570684 (Intron
Variant) T > A,C
This meta-analysis 0.01 0.01 0.01 0.01 0.01
Northern Sweden 0.007 0.007 0.007 0.007 0.035
TWINSUK 0.008 0.008 0.008 0.007 0.007
ALSPAC 0.010 0.010 0.010 0.008 0.004
Estonian 0.018 0.018 0.018 0.018 0.015
GnomAD 0.079 0.074 0.080 0.020 0.089
TOPMED 0.083 0.076 0.083 0.017 0.096
1000Genomes 0.106 0.100 0.107 0.037 0.128
Minor allele frequency as reported in dbSNP, available online at https://www.ncbi.nlm.nih.gov/snp/. NorthernSweden
from the Northern Sweden Population Health Study, TWINSUK from the TwinsUK registry study, ALSPAC from
the Avon Longitudinal Study of Parents and Children, Estonian from the Estonian Biocentre, GnomAD from The
Genome Aggregation Database, TOPMED from the Trans-Omics for Precision Medicine (TOPMed) Program of the
NIH National Heart, Lung and Blood Institute and 1000 Genomes from the International Genome Sample Resource
and 1000 Genomes project.
In the NOPHO cohort, heterozygotes (AC) had a 6/28 (21.4%) risk of VTE, whereas homozygotes
for the non-risk allele (CC) had a 54/836 (6.5%) risk of VTE. In the ERASE cohort, heterozygotes (AC)
had a 6/24 (25%) risk of VTE, and homozygotes CC had a 29/678 (4.3%) risk of VTE. There were no
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homozygotes for the risk allele. Thus, in the overall cohort, risk of VTE for the AC genotype was 23%
and for homozygous CC was 5.4%.
In total, there were three SNPs in ALOX15B at p < 1 × 10−6 that were associated with development
of VTE (Table 2 and Supplementary Table S1). The two other SNPs were rs7225107, located in the coding
region of ALOX15B and rs140958758, which is located close to the 3′end of the transcript. All three
SNPs are in LD, where rs1804772 and rs7225107 are in complete LD (D’ = 1, r2 = 1), while rs140958758
is in moderate LD (D’ = 1, r2 = 0.69) [11].
ALOX15B has a function in lipid metabolism and arachidonic acid metabolism, and increased
expression leads to platelet aggregation in vitro [12]. Thus, variants within the ALOX15B gene or
regulatory regions are biologically plausible candidates for treatment-related VTE in patients treated
for ALL/LBL.
KALRN, kalirin RhoGEF kinase, located at 3q21.1, was the second-ranked candidate associated
with VTE in our study (top SNP rs570684, p = 4.34 × 10−7, MAF 1%, OR 0.11 (95%CI 0.05–0.26)).
KALRN encodes a protein kalirin, with diverse functions including RhoGDP/GTP exchange and
inhibition of inducible nitric oxide synthase in neuronal cells [13]. This was the only SNP identified at
this locus. Despite a difference in the effect size between the ERASE and NOPHO cohorts (Table 2),
we believe that the KALRN SNP it is a potential candidate worthy of validation in external other cohorts.
It is relevant to thrombosis that KALRN and associated SNPs confer increased risk of ischemic
stroke [14], atherosclerosis and early-onset coronary artery disease [15].
Within the additional loci that had an association p < 5 × 10−6 with VTE, we also identified SNP
rs140514603 in RIN3 (Ras and Rab interactor 3, 14q32.12). RIN3 missense mutations have been found
to predispose to Paget’s disease of bone [16]. RIN3, specifically rs3742717, was found to be important
in a whole-exome study of VTE in childhood ALL [8]. These two SNPs (rs140514603 and rs3742717)
are not in LD (D’ = 0.76, r2 = 0.001).
A candidate SNP analysis of the NOPHO cohort identified a significant association between
VTE and F11 rs2036914 (hazard ratio (HR) 1.52, 95%CI 1.11–2.07), a borderline significant association
with FGG rs2066865 (HR 1.37, 95%CI 0.99–1.91) but no association with either ABO rs8176719 or F5
rs6025 [17]. In contrast, in the ERASE VTE study, no significant associations were found between
SNPs associated with VTE in non-cancer populations (Table S2) and VTE in the ERASE cohort [4].
We repeated this analysis using the meta-analysis dataset but did not find any significant association
between SNPs associated with VTE in the non-cancer population and VTE in ALL patients (Table S3).
The F11 rs2036914 SNP was not in the meta-analysis dataset, but there was no significant association
with 4 other F11 SNPs rs925451, rs4253417, rs3756011, rs2289252 (Table S3). We did not reproduce
the borderline significant association between VTE and FGG rs2066865 (minor allele frequency 0.25,
p = 0.66, odds ratio 1.07 (0.76–1.52, 95% confidence interval)) (Table S3). Concordant with the NOPHO
analysis we did not identify a significant association between ALL VTE and 21 SNPs in the ABO
gene or in linkage disequilibrium with rs8176719 (Table S3). In the meta-analysis dataset, there was
no significant association between FVL rs6025 (minor allele frequency 0.02, p = 0.36, odds ratio 1.46
(0.64–3.31, 95% confidence interval)), concordant with the NOPHO data [17].
3. Discussion
To our knowledge, this is the first GWAS meta-analysis that has been reported for childhood
ALL/LBL-related symptomatic venous thrombosis. This study was performed after excluding
individuals on non-Caucasian ancestry to reduce confounding due to population stratification.
Combining two large international cohorts, there were 92 cases and 1481 controls, with calculated 80%
power to detect SNPs present at MAF ≥5% with a genotype relative risk of 3.2. Despite this, we did
not detect a genome-wide significant candidate. We were not able to demonstrate an association
between SNPs associated with VTE in non-cancer populations and VTE occurring in ALL patients.
Whilst there are limitations to the power of our meta-analysis, the data suggest that there may be
distinct pathophysiologic mechanisms underlying VTE in ALL patients compared to VTE in non-cancer
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populations. Top candidate SNPs were associated with ALOX15B (rs1804772) and KALRN (rs570684)
(p < 1 × 10−6). A strength of this study is that the top SNPs were identified despite the heterogeneity of
treatment protocols. If validated, these top SNPs could uncover genetic susceptibility mechanisms for
VTE. This may assist with identifying a population of children at highest risk of VTE during therapy
for ALL/LBL, who may benefit from thromboprophylaxis [7,18].
Several lines of evidence demonstrate that proteins implicated from this GWAS are functionally
important for platelet activation (ALOX15B [12]), lipid mobilization/atherosclerosis (ALOX15B [12],
kalirin [15]) and endothelial function (kalirin [19]).
The top SNP rs1804772 is associated with gene expression changes in tibial artery tissue, via a linked
gene KRBA2 (Open Targets Platform, https://www.targetvalidation.org, accessed July 17 2019, [20]).
ALOX15B and direct metabolic by-products, including 15-hydroxyeicosatetraenoic acid, have a role
in atherosclerosis and ischemic stroke in adults [12]. ALOX15B is induced following macrophage
activation by pro-inflammatory cytokines and lipids [12]. Increased expression of ALOX15B induced
platelet aggregation and increased thrombin generation that was independent of tissue factor [12]
and in vitro modelling in the same study demonstrated that knockdown of ALOX15B reversed the
thrombogenic phenotype. Pharmacological inhibition of ALOX12/15 in a mouse model of ischemic
stroke led to neuronal protection and improved behavioural outcomes [21].
Kalirin, encoded by KALRN, is present in extracellular vesicles secreted by TNF-α-activated
venous endothelial cells in vitro [19]. KALRN expression resulted in inhibition of inducible nitric oxide
synthase (iNOS) in pituitary cells in vivo and a possible neuroprotective effect [13]; thus further study
of kalirin and iNOS induction in endothelial cells may be important.
If validated, the top SNPs may reveal new avenues for further study in ALL/LBL-related VTE.
One testable hypothesis is that lipid and cytokine-induced inflammation during ALL therapy leads to
platelet activation, venous endothelial dysfunction and altered thrombotic risk. This inflammatory
process could be altered by genetic polymorphisms (such as those identified in this study),
chemotherapy [6,22] and/or other environmental factors such as infection [3,4]. Supporting evidence
includes that asparaginase and steroids act synergistically to increase circulating serum lipids and
triglycerides [22–24] with a possible increased thrombotic risk [22]; and that platelets are known
to express receptors for cytokines and oxidised lipids on their cell membrane, such as CD36 [25].
Thus, through improved understanding of thrombogenic mechanisms in ALL/LBL, there may be
potential to exploit tissue and endothelial protection.
Results of the current study and a recent whole-exome study [8] also warrant further study of the
function of RIN3 in ALL/LBL treatment-related VTE.
This study highlights challenges and limitations in conducting a GWAS to investigate ALL
treatment-related VTE. Large cohort studies are required to provide sufficient power to detect variants
associated with rare conditions. This is in order to refute the null hypothesis, that there are no
SNPs associated with the phenotype at GWS levels (p < 5 × 10−8). The GWAS meta-analysis was
underpowered to detect SNPs with MAF <5% and genotype relative risk <3.2 [26]. To detect SNPs with
MAF 5% and associated genotype relative risk of 2, with 80% power, 444 cases were required. This also
demonstrates that in order to detect SNPs with a weaker effect on the phenotype, very large cohorts are
required. Secondly, most GWA studies are conducted in homogenous ethnic populations, to reduce
risk of population stratification [27]. As this GWAS was conducted in children and adolescents of
Caucasian ancestry, results cannot be extrapolated to non-Caucasian populations. The incidence of VTE
between the NOPHO2008 and ERASE cohorts was 6.1% and 5.1% respectively [2,4]. The meta-analysis,
as outlined in the patients and methods and consort diagrams (Figures 1 and 2), includes the subset of
NOPHO and ERASE patients with available DNA samples, Caucasian ancestry and where the sample
passed quality control. As a result of sample availability and filtering, 61/63 NOPHO VTE cases were
included in the meta-analysis. In contrast, there was a lower proportion of ERASE VTE cases included
in meta-analysis (31/52) due to the filtering criteria. Finally, there was heterogeneity in the timing of VTE
events between the ERASE and NOPHO cohorts, likely due to asparaginase scheduling, with VTE events
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occurring significantly earlier in the ERASE cohort. For NOPHO2008, patients received asparaginase
therapy from week 4 to week 36, during the consolidation, delayed intensification and maintenance
phases of treatment [2]. In contrast, patients in the ERASE cohort received asparaginase therapy
during induction therapy (weeks 1–5) and re-induction therapy (weeks 24–28) [4]. This limitation
will be difficult to overcome in larger international GWA studies, due to variation in ALL treatment
protocols worldwide.
4. Patients and Methods
We conducted two separate genome-wide association studies—one in a Nordic Society of Pediatric
Hematology and Oncology (NOPHO) cohort comprising 61 cases and 805 controls, and one in an
Australian cohort (ERASE), comprising 31 cases and 676 controls. Cases were defined as patients who
had experienced a symptomatic VTE (termed “VTE” in this study) during first-line ALL therapy, while
controls had not experienced a symptomatic VTE.
NOPHO GWAS: All included patients were diagnosed with B-cell precursor, T-cell ALL or
mixed-phenotype acute leukemia (MPAL) between 2008 and 2017 and were treated according to the
NOPHO ALL2008 protocol. Patients were aged between 1 and 17 years inclusive. This protocol
and the occurrence of thromboembolism in the cohort have been described in detail elsewhere [2,3].
All patients with Down syndrome were excluded. Included cases had all experienced a symptomatic
VTE, according to the Ponte di Legno Toxicity Working Group (PTWG) severity grade 2A or higher [28].
We excluded all controls that did not complete their full PEG-asparaginase therapy as prescribed in
the protocol. Asparaginase is used from consolidation onwards in the NOPHO ALL2008 protocol,
and anticipated asparagine depletion is from Week 5 to Week 35 [29].
Genotyping was performed on the Illumina Infinium Omni 2.5exome-8-BeadChip using DNA
from remission blood samples. We removed SNPs with a genotype call rate <98%, a minor allele
frequency (MAF) <1%, or with evidence of Hardy–Weinberg deviation (p < 5 × 10−6). Samples were
filtered based on individual missingness (>2%), excess heterozygosity (±4 standard deviations (SD)),
mismatch between sex according to genotype and clinical data, and related individuals (as determined
by identity-by-state estimates). Genetic ancestry was determined by multidimensional scaling analysis
including HapMap reference samples and excluded all patients >15 SD from the European (CEU,
Utah Residents (CEPH) with Northern and Western European Ancestry) cluster mean. The NOPHO
cohort consort diagram is shown in Figure 1. Association analyses based on 1,446,007 available SNPs
were conducted using logistic regression with adjustment for age, sex, risk group, and genetic ancestry
as determined by principal components analysis.
Evaluation of ALL Treatment-related Side-Effects (ERASE) GWAS: Included patients were diagnosed
with ALL or lymphoblastic lymphoma (LBL) between 1998 and 2013 in Australia, aged between 1
and 18 years inclusive, and treated on one of the following BFM-based protocols: ANZCCSG study
7, ANZCHOG study 8, BFM-95, COG A5971, or AIEOP-BFM study 9 [30–34]. LBL patients were
included, as they were treated on the same protocols as patients diagnosed with ALL. The ERASE
study has been described in detail previously [4]. In contrast to NOPHO ALL2008, asparaginase is
used in the induction phase in BFM-based protocols. Patients were excluded as controls if they had
less than 18 months of follow up after diagnosis. Thromboembolic events were classified according to
the Common Terminology Criteria for Adverse Events (CTCAE) [35], and all grades of symptomatic
events were included as cases.
Germline DNA was genotyped on the Illumina Infinium Oncoarray-530K BeadChip. Samples were
filtered by individual missingness (>3%), sex mismatch, and related individuals. We removed SNPs
with a genotype call rate < 97%, MAF < 1%, and Hardy–Weinberg p value < 10−4. The association
analyses were restricted to patients of Caucasian ancestry, as defined by <6 SD from the following
groups in the 1000 Genomes reference panel [36]: IBS (Iberian population in Spain), TSI (Toscani in Italy),
GBR (British in England and Scotland), CEPH (Utah residents with Northern and Western European
ancestry), and FIN (Finnish in Finland). The ERASE cohort consort diagram is shown in Figure 2. After
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quality control, imputation analysis (reference panel 1000 Genomes European) was performed using
IMPUTE2 [37] and the analysis excluded imputed SNPs with an information score <0.4, resulting
in 10, 922, 652 SNPs available for analysis. The GWAS was performed as a logistic regression with
adjustment for age, sex and genetic ancestry as determined by principal component analysis.
Meta-analysis: After the two separate GWA studies, we carried out a meta-analysis in METAL,
using the Standard Error SE model (STDERR) which takes into account effect size estimates and
standard errors [10].
With 80% power, the GWA meta-analysis could detect VTE-associated SNPs of a MAF ≥ 6% with
a relative risk (RR) of 3.2 for the minor allele; or a MAF ≥ 5% and a RR of 3.5; or a MAF of 3–4% and
a RR at or above 4.0 [26].
Top SNPs: For SNPs in the GWAS meta-analysis, the following data were reviewed: P value,
minor allele frequencies, odds ratio (OR), OR 95% confidence interval, annotated gene, and genomic
position. The top SNPs were those that had p values from the METAL analysis of p < 5 × 10−6.
The annotated gene was determined by cross-referencing available online genome browsers Refseq [38],
ensembl 74 [39] and UCSC database information (GRCh37/hg19, 2015 update [40]) accessed through
SNPnexus (2012 update, [41]). The SNPnexus database (http://www.snp-nexus.org) is kept synchronised
with the UCSC human genome annotation database (http://genome.ucsc.edu). Where there was
discrepancy or the gene was uncertain, a search was performed manually using NCBI dbSNP build
151 [42]. Linkage disequilibrium (LD) of candidate SNPs was examined using the LDlink online tool
(https://ldlink.nci.nih.gov) [11].
We had previously compiled a list of germline SNPs associated with VTE in the non-cancer
population based on several adult series, one pediatric study and SNPs identified through dbSNP build
149 (Supplementary Table S2) [9,43–49]. The list of SNPs which was expanded to include additional
SNPs in complete linkage disequilibrium (r2 = 1), using the SNP annotation and proxy (SNAP) search
tool with HapMap genomic data [50].
Ethics statement: This study and database were approved by the relevant local and national ethical
bodies from Denmark (for NOPHO, approval H-2.2010-002) and Australia (for the ERASE Study).
The ERASE study was approved by the Hunter New England Human Research Ethics Committee
(HNEHREC Reference Number: 12/11/21/4.01).
5. Conclusions
In summary, we have identified biologically plausible candidate SNPs that associate with risk of
VTE in childhood ALL therapy across two international cohorts which require validation in future
studies. A large international GWAS with capacity for discovery and validation cohorts would
help advance the field of understanding in childhood ALL/LBL-related thrombosis. Such a study is
currently being designed within the PTWG. A genotype risk signature could also be considered to
assess cumulative risk with combinations of risk alleles [17]. A reduction in phenotypic variation,
by selection of a VTE subtype such as CVST, may also increase the strength of association and risk
effect exerted by candidate SNPs.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/5/1285/s1,
Table S1: SNPs associated with VTE in meta-analysis, p < 5 × 10−6, Table S2: SNPs associated with VTE in
the non-cancer population, Table S3: Lookup table of SNPs associated with VTE in non cancer patients in
this meta-analysis.
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